Skip to main content
Retour
ANAB logo

AnaptysBio, Inc.

Qualité des données : 100%
ANAB
NASDAQ Healthcare Biotechnology
62,72 €
▲ 0,36 € (0,57%)
Cap. Boursière : 1,80B
Fourchette du Jour
62,01 € 65,20 €
Fourchette 52 Semaines
15,40 € 68,39 €
Volume
408 549
Moyenne 50J / 200J
53,61 € / 36,18 €
Clôture Précédente
62,37 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -136,3 0,4
P/B 48,5 2,9
ROE % -24,5 3,8
Net Margin % -5,6 3,9
Rev Growth 5Y % 38,8 10,0
D/E 0,4 0,2

Points Clés

Revenue grew 38,82% annually over 5 years — strong growth
Debt/Equity of 0,38 — conservative balance sheet
Generating 19,61M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 118,19%
Capital efficient — spends only 0,04% of revenue on capex
ROIC of 69,99% — excellent capital efficiency

Croissance

Revenue Growth (5Y)
38,82%
Revenue (1Y)157,01%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-24,49%
ROIC69,99%
Net Margin-5,64%
Op. Margin20,42%

Sécurité

Debt / Equity
0,38
Current Ratio9,07
Interest Coverage0,60

Valorisation

P/E Ratio
-136,27
P/B Ratio48,46
EV/EBITDA32,97
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 157,01% Revenue Growth (3Y) 269,78%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 38,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 234,60M Net Income (TTM) -13,23M
ROE -24,49% ROA -3,63%
Gross Margin 98,97% Operating Margin 20,42%
Net Margin -5,64% Free Cash Flow (TTM) 19,61M
ROIC 69,99% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,38 Current Ratio 9,07
Interest Coverage 0,60 Dividend Yield 0,00%
Valuation
P/E Ratio -136,27 P/B Ratio 48,46
P/S Ratio 7,69 PEG Ratio 1,12
EV/EBITDA 32,97 Dividend Yield 0,00%
Market Cap 1,80B Enterprise Value 1,58B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 234,60M 91,28M 17,16M 10,29M 63,18M
Net Income -13,23M -145,23M -163,62M -128,72M -57,80M
EPS (Diluted) -0,46 -5,12 -6,08 -4,57 -2,11
Gross Profit 232,18M -72,56M -115,13M -78,51M -35,32M
Operating Income 47,90M -114,95M -164,41M -115,15M -56,81M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 364,40M 483,83M 452,39M 610,38M 643,07M
Total Liabilities 327,19M 412,97M 364,29M 348,28M 286,64M
Shareholders' Equity 37,21M 70,87M 88,10M 262,10M 356,43M
Total Debt 14,11M 369,46M 17,81M 19,45M 20,96M
Cash & Equivalents 238,20M 123,08M 35,97M 71,31M 495,73M
Current Assets 350,25M 431,88M 406,84M 447,21M 553,88M
Current Liabilities 38,63M 45,43M 37,44M 26,05M 16,10M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#8 of 146
76

Activité Récente

Entré Full Throttle
Mar 24, 2026